Skip to main content
Clinical Trials/NCT01477203
NCT01477203
Completed
Phase 4

Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders

Medical University of Vienna1 site in 1 country289 target enrollmentNovember 2011

Overview

Phase
Phase 4
Intervention
Escitalopram
Conditions
Major Depressive Disorder (MDD)
Sponsor
Medical University of Vienna
Enrollment
289
Locations
1
Primary Endpoint
SSRI induced changes in BOLD (blood oxygen level dependent) response over time
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

MAN-BIOPSY pursues the concrete research question whether novel biological and psycho-physiological clusters or categories can be defined to improve treatment and minimize side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and endocrinological parameters. One major aspect of our research approach is its focuses on the identification of dysfunctions in fundamental information processing mechanisms and neurocomputational mechanisms, and is not restricted to symptom-oriented tasks.

The main objectives of MAN-BIOPSY are therefore

  • to identify biological and psycho-physiological parameters for major depressive disorders and anxiety disorders, and
  • to identify predictive markers for treatment response and type/severity of side effects for these disorders.
Registry
clinicaltrials.gov
Start Date
November 2011
End Date
September 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rupert Lanzenberger

A/Prof.PD.Dr.

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • concomitant major internal or neurological illness
  • concomitant psychiatric disorders (except depression and anxiety for patients, excluding PTSD, claustrophobia and bipolar disorder)
  • ingestion of any antipsychotic, antidepressant, or anti-anxiety agent within the last three months prior to the screening visit
  • current substance abuse
  • failure to comply with the study protocol or to follow the instructions of the investigating team

Arms & Interventions

Escitalopram

50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication

Intervention: Escitalopram

Outcomes

Primary Outcomes

SSRI induced changes in BOLD (blood oxygen level dependent) response over time

Time Frame: 4 vears

SSRI induced changes in ERPs (event-related potentials) over time

Time Frame: 4 years

Secondary Outcomes

  • biochemical data(4 years)

Study Sites (1)

Loading locations...

Similar Trials